Mar 31 2008, 7:00 AM EST
News source: Business Wire
BioForce Nanosciences Holdings, Inc. (OTC BB: BFNH), a producer of integrated biological and mechanical systems for life science researchers at the micro and nano scales, today announced record revenue and gross profit for the fourth quarter and full year ended December 31, 2007.
Fourth Quarter Highlights
-- Net revenues were a record $545,622 for the fourth quarter of 2007, a 256% increase from net revenues of $153,459 for the fourth quarter of 2007.
-- Gross profit was a record $378,356 for the fourth quarter of 2007, a 581% increase from gross profit of $55,584 for the fourth quarter of 2006.
-- Net loss on common stock was $597,669 ($0.02 per fully diluted share) for the fourth quarter of 2007, as compared to a net loss on common stock of $1,163,259 ($0.05 per fully diluted share) for the fourth quarter of 2006.
2007 Highlights
-- Net revenues were a record $1,125,030 for the year ended December 31, 2007, a 171% increase from net revenues of $415,087 for the year ended December 31, 2006.
-- Gross profit was a record $523,846 for the year ended December 31, 2007, a 143% increase from gross profit of $215,938 for the year ended December 31, 2006.
-- Net loss on common stock was $4,009,833 ($0.17 per fully diluted share) for the year ended December 31, 2007, as compared to a net loss on common stock of $3.974,083 ($0.17 per fully diluted share) for the year ended December 31, 2006.
Operations Review
Kerry Frey, President and Chief Executive Officer of BioForce, said, "This was a good year and a great quarter for BioForce. We sold nine Nano eNabler(TM) systems during 2007, as compared to two Nano eNabler(TM) systems during 2006. Of those nine sales during 2007, five occurred during the fourth quarter of the year. For the year six of our nine Nano eNabler(TM) system sales were to overseas customers. Our loss for the fourth quarter of 2007 narrowed dramatically from the results in prior quarters, and we remain focused upon achieving profitability.
"During 2007 we made the transition from a development stage company to a commercial enterprise. We have also proved ourselves capable of operating as a global company. International sales represent a significant portion of our business, with our distributors doing a great job of helping us penetrate the market in Europe and Asia."
Frey continued, "We continued to develop our intellectual property portfolio in 2007. Just touching on the highlights, we received notice from the U.S. Patent and Trademark Office (USPTO) that our ``Protein Nanoarray'' patent had been upheld, a Notice of Allowance from the USPTO for our Sindex(TM) chips, and a Notice of Allowance from the USPTO for our Chip-On-A-Tip(TM) patent.
"In 2007 we saw the Nano eNabler(TM) system adopted by customers for a variety of research activities, with two key areas being cell biology and biosensor development. The Nano eNabler's ability to deposit miniscule quantities of biological materials with extremely high precision and flexibility allows for the creation of biological microenvironments necessary to study cellular growth at the single cell level, and development of ultra-miniaturized diagnostic tests and devices. Ultimately, these could lead to breakthrough discoveries in the areas of cancer therapy, stem cell therapy and tissue engineering, as well as development of diagnostic tests with increased sensitivity and requiring far less source material.
Frey concluded, "We anticipate that 2008 will be another good year for us as we introduce new products to the market, and as the effect of our enhanced sales team begins to show in further sales. I am pleased to announce that the sales momentum developed during 2007 has continued into 2008, w
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All